Tuberculosis sepsis after tocilizumab treatment

Clin Microbiol Infect. 2020 Nov;26(11):1493-1494. doi: 10.1016/j.cmi.2020.05.030. Epub 2020 Jun 5.

Authors

A C Reisinger¹, J Hermann², F R Vagena³, G Hackl⁴, P Eller⁴

Affiliations

¹ Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria. Electronic address: [email protected].
² Department of Internal Medicine, Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria.
³ Department of Pathology, Medical University of Graz, Graz, Austria.
⁴ Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Drug Therapy, Combination
Ethambutol / therapeutic use
Female
Humans
Isoniazid / therapeutic use
Middle Aged
Multiple Organ Failure / drug therapy
Multiple Organ Failure / etiology*
Mycobacterium tuberculosis / genetics
Mycobacterium tuberculosis / isolation & purification
Pyrazinamide / therapeutic use
Rifampin / therapeutic use
Sepsis / chemically induced
Sepsis / diagnostic imaging*
Sepsis / drug therapy
Treatment Outcome
Tuberculosis / chemically induced
Tuberculosis / diagnosis*
Tuberculosis / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Pyrazinamide
Ethambutol
tocilizumab
Isoniazid
Rifampin